The impact of comorbidity on cancer survival: a review
Mette Søgaard,Reimar W. Thomsen,Kristine Skovgaard Bossen,Henrik Toft Sørensen,Mette Nørgaard +4 more
Reads0
Chats0
TLDR
In general, comorbidity does not appear to be associated with more aggressive types of cancer or other differences in tumor biology, and it is unclear from the literature whether the apparent undertreatment reflects appropriate consideration of greater toxicity risk, poorer clinical quality, patient preferences, or poor adherence among patients with comor bidity.Abstract:
Background A number of studies have shown poorer survival among cancer patients with comorbidity. Several mechanisms may underlie this finding. In this review we summarize the current literature on the association between patient comorbidity and cancer prognosis. Prognostic factors examined include tumor biology, diagnosis, treatment, clinical quality, and adherence. Methods All English-language articles published during 2002-2012 on the association between comorbidity and survival among patients with colon cancer, breast cancer, and lung cancer were identified from PubMed, MEDLINE and Embase. Titles and abstracts were reviewed to identify eligible studies and their main results were then extracted. Results Our search yielded more than 2,500 articles related to comorbidity and cancer, but few investigated the prognostic impact of comorbidity as a primary aim. Most studies found that cancer patients with comorbidity had poorer survival than those without comorbidity, with 5-year mortality hazard ratios ranging from 1.1 to 5.8. Few studies examined the influence of specific chronic conditions. In general, comorbidity does not appear to be associated with more aggressive types of cancer or other differences in tumor biology. Presence of specific severe comorbidities or psychiatric disorders were found to be associated with delayed cancer diagnosis in some studies, while chronic diseases requiring regular medical visits were associated with earlier cancer detection in others. Another finding was that patients with comorbidity do not receive standard cancer treatments such as surgery, chemotherapy, and radiation therapy as often as patients without comorbidity, and their chance of completing a course of cancer treatment is lower. Postoperative complications and mortality are higher in patients with comorbidity. It is unclear from the literature whether the apparent undertreatment reflects appropriate consideration of greater toxicity risk, poorer clinical quality, patient preferences, or poor adherence among patients with comorbidity. Conclusion Despite increasing recognition of the importance of comorbid illnesses among cancer patients, major challenges remain. Both treatment effectiveness and compliance appear compromised among cancer patients with comorbidity. Data on clinical quality is limited.read more
Citations
More filters
Journal ArticleDOI
Influence of the time interval from diagnosis to treatment on survival for early-stage liver cancer
TL;DR: Being male, being elderly, having a higher CCI level, and being treated in a hospital with a low service volume were factors associated with a poorer prognosis.
Journal ArticleDOI
First results from five multidisciplinary diagnostic centre (MDC) projects for non-specific but concerning symptoms, possibly indicative of cancer.
D Chapman,Poirier,Daniel Vulkan,Karen Fitzgerald,Greg Rubin,William Hamilton,Stephen W. Duffy +6 more
TL;DR: The MDC model diagnoses cancer in patients with non-specific symptoms, with a conversion rate of 8%, demonstrating the diagnostic potential of a non-site-specific symptomatic referral pathway.
Journal ArticleDOI
Health-Related Quality of Life in a Predictive Model for Mortality in Older Breast Cancer Survivors.
TL;DR: A predictive model and risk score for 10‐year mortality using health‐related quality of life (HRQOL) in a cohort of older women with early‐stage breast cancer is developed.
Journal ArticleDOI
Digital imaging in the immunohistochemical evaluation of the proliferation markers Ki67, MCM2 and Geminin, in early breast cancer, and their putative prognostic value
Shalaka Joshi,Johnathan Watkins,Patrycja Gazinska,John Brown,Cheryl Gillett,Anita Grigoriadis,Sarah E Pinder +6 more
TL;DR: Digital microscopy can be used effectively as a high-throughput method to evaluate immunohistochemical expression and all 3 proliferation marker cutoffs were predictive of 15-year breast cancer-specific survival in univariable Cox regression analyses.
Journal ArticleDOI
The nature of early-stage endometrial cancer recurrence—A national cohort study
Mette Moustgaard Jeppesen,Pernille Tine Jensen,Dorte Gilså Hansen,Maria Iachina,Ole Mogensen,Ole Mogensen +5 more
TL;DR: A comprehensive analysis of disease recurrence in a large Danish cohort of women with early-stage endometrial cancer treated according to national guidelines to improve recurrence prediction and to reduce morbidity and mortality is presented.
References
More filters
Journal ArticleDOI
A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation☆
TL;DR: The method of classifying comorbidity provides a simple, readily applicable and valid method of estimating risk of death fromComorbid disease for use in longitudinal studies and further work in larger populations is still required to refine the approach.
Journal ArticleDOI
Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study
TL;DR: The findings challenge the single-disease framework by which most health care, medical research, and medical education is configured, and a complementary strategy is needed, supporting generalist clinicians to provide personalised, comprehensive continuity of care, especially in socioeconomically deprived areas.
Journal ArticleDOI
A dictionary of epidemiology
TL;DR: The new edition of this classic text remains the definitive dictionary in epidemiology, and the dictionary goes beyond simple definitions, as it place each term firmly and clearly in its fuller epidemiologic context.
Journal ArticleDOI
Underrepresentation of patients 65 years of age or older in cancer-treatment trials.
TL;DR: There is substantial under representation of patients 65 years of age or older in studies of treatment for cancer, and the reasons should be clarified, and policies adopted to correct this underrepresentation.
Journal ArticleDOI
Cumulative illness rating scale.
TL;DR: A Cumulative Illness Rating Scale, designed to meet the need for a brief, comprehensive and reliable instrument for assessing physical impairment, has been developed and tested and is well suited to a variety of research uses.